Enhanced expression of KIF4A in colorectal cancer is associated with lymph node metastasis

YOSHIKO MATSUMOTO, MOTONOBU SAITO, KATSUHARU SAITO, YASUYUKI KANKE, YOHEI WATANABE, HISASHI ONOZAWA, SUGURU HAYASE, WATARU SAKAMOTO, TERUHIDE ISHIGAME, TOMOYUKI MOMMA, KENSUKE KUMAMOTO, SHINJI OHKI and SEIICHI TAKENOSHITA

Department of Organ Regulatory Surgery, School of Medicine, Fukushima Medical University, Fukushima 960-1295, Japan

Received May 24, 2016; Accepted January 19, 2017

DOI: 10.3892/ol.2017.7555

Abstract. Kinesin family member 4A (KIF4A) is a member of the kinesin 4 subfamily of kinesin-related proteins and serves an important role in cell division. The expression levels of KIF4A have been investigated in numerous types of cancer, including cervical, lung, oral, and breast cancer, and are established to be associated with poor patient prognosis. However, the role of KIF4A, as well as its expression in colorectal cancer (CRC), remains to be elucidated. Therefore, the current study investigated KIF4A expression levels in patients with CRC and demonstrated that its levels were increased in tumor tissues compared with non-tumor tissues. To investigate the functional role of KIF4A, KIF4A was knocked down in CRC cells and cell viability was evaluated. CRC cells with KIF4A knockdown exhibited lower cell proliferation compared with control cells. In addition, KIF4A expression levels, as determined by immunohistochemistry, were compared with the expression of Ki-67, but no significant associations were observed in the patients with CRC. Therefore, KIF4A was found to be upregulated in patients with CRC and downregulation of KIF4A reduced cell proliferation in CRC cells. These results suggest that KIF4A may be a potential therapeutic target, which may improve the outcomes of patients with CRC.

Introduction

Colorectal cancer (CRC) is the third most frequently diagnosed cancer in males and females in the United States (1). As surgery alone is not sufficient to cure the majority of patients with CRC, adjuvant chemotherapy or radiation therapy is also typically administered to patients (2). A combination of chemotherapy with folinic acid, 5-fluorouracil and oxaliplatin and folinic acid, 5-fluorouracil and irinotecan has become the standard treatment regimen for patients with CRC, providing a higher response rate compared with conventional chemotherapy (3-6). However, the response rates of current chemotherapy regimes are <50% and therefore, alternative molecular targets are required to improve drug response rates (3-6).

The kinesin superfamily proteins (KIFs) are microtubule-dependent molecular motors that convert the chemical energy from ATP hydrolysis to the mechanical action of transporting cargo along microtubules, suggesting that they have an important role in intracellular transport and cell division (7). KIFs are classified into 14 distinct families with varying structural and functional characteristics (8,9). Among these, KIF4A is considered to have a role in chromosome condensation and is involved in the segregation machinery that functions in mitotic division (10,11). Alterations in the regulation of KIF4A promote abnormal spindle separation and lead to aneuploidy in daughter cells (10). Cells with aneuploidy are characterized by loss or gain of genetic material (11). Therefore, KIF4A expression levels may be associated with cancer progression.

It has been reported that KIF4A expression is altered in numerous types of cancer, including cervical (12), lung (13), gastric (14), oral (15) and breast cancer (16). These alterations in cancer cells suggest that the biological function of KIF4A is associated with the regulation of the cell cycle and cellular proliferation. A previous microarray study found that there was increased expression of KIF4A mRNA in human cervical cancer (12). KIF4A expression was identified as being upregulated in lung cancer and was significantly associated with the male gender, non-adenocarcinoma histology and a reduced survival rate in patients with non-small cell lung cancer (13). In an immunohistochemical (IHC) evaluation of 106 patients with oral squamous cell cancer, KIF4A expression levels in cancer tissue were significantly increased compared with those in normal tissue (15). A previous study demonstrated that estrogen induces a number of KIFs, including KIF4A, and increased levels of KIF4A are associated with reduced relapse-free survival of patients with breast cancer that are positive for the estrogen receptor (16). These previous studies indicated that KIF4A may function as an oncogene in a numerous types of cancer, but the expression and role of KIF4A in CRC remain to be elucidated. The present study...
investigated the biological significance of KIF4A expression levels to clarify the function of KIF4A in CRC.

Materials and methods

Clinical tissue samples from patients. A total of 258 surgical specimens were obtained for analysis from 258 patients with CRC that underwent surgical resection at Fukushima Medical University Hospital (Fukushima, Japan) between January 1991 and December 2011. In 63/258 of the tissues, mRNA was extracted from cancer tissue and adjacent non-tumor tissue. Information regarding age, gender, tumor-mode-metastasis (TNM) stage (the 7th classification) (17,18) and pathological diagnosis, including lymphatic and venous invasion, were retrospectively collected. At the time of primary tumor resection, carcinoma tissues were staged according to the Union for International Cancer Control classification (17,18). Written informed consent was obtained from all patients. This study was approved by the Ethics Committee of Fukushima Medical University (ref. no. 2117).

Cell line culture. The RKO, SW480, Lovo, HCT15, SW48, LS174T, SW620, LS180 and HCT116 colon cancer cell lines were used in this study and all were obtained from the American Type Culture Collection (Manassas, VA, USA). The cells were cultured in the recommended media (Dulbecco’s modified Eagle’s medium; Thermo Fisher Scientific, Inc., Waltham, MA, USA) for RKO, LS174T and LS180 and Roswell Park Memorial Institute-1640 medium (Sigma-Aldrich; Thermo Fisher Scientific, Inc.) for SW480, Lovo, HCT15, SW48, SW620 and HCT116 supplemented with 10% fetal bovine serum (Thermo Fisher Scientific, Inc.). Cells were maintained in a 37°C incubator in an atmosphere containing 5% CO2.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Total RNA was extracted from RKO, SW480, Lovo, HCT15, SW48, LS174T, SW620, LS180 and HCT116 cells using TRIzol® reagent (Thermo Fisher Scientific, Inc.) according to the manufacturer’s protocol as previously described (19). Complementary DNA (cDNA) was synthesized from 5 µg of total RNA with a random hexamer using the SuperScript® III First-Strand Synthesis System (Thermo Fisher Scientific, Inc.). These cDNAs were used for the measurement of gene expression with an Applied Biosystems™ 7500 Real-time PCR system (Thermo Fisher Scientific, Inc.) using TaqMan™ probes of KIF4A and β-actin which were used as internal controls (KIF4A, #HS01020169_m1; β-actin, #Hs99999903_m1; Thermo Fisher Scientific, Inc.) and experiments were performed in triplicate with blinded patient information. The thermocycling conditions were as follows: 50°C for 2 min for AMPerase activation, 95°C for 10 min for Taq activation, 95°C for 15 sec for denaturation and 60°C for 1 min for annealing and extension. Relative KIF4A gene expression was calculated using the 2^ΔΔCt method (20).

IHC staining and evaluation. IHC staining was performed on paraffin-embedded histological sections (4-µm thick) using a polymer peroxidase method, in which colon cancer specimens were fixed in 20% phosphate-buffered formalin (pH 7.4) at room temperature overnight. Briefly, following deparaffinization with xylene and rehydration using alcohol-water mixtures, prior to heat treatment in 10 mM citric acid (pH 6.0) for antigen retrieval, the sections were treated with 0.3% hydrogen peroxide in methanol for 30 min to block endogenous peroxidase activity. Following washing with PBS, the sections were incubated with rabbit polyclonal anti-KIF4A antibody (dilution, 1:300; #ab122227; Abcam, Cambridge, UK) and mouse monoclonal anti-MIB-1 (Ki-67) antibody (dilution, 1:100; Dako; Agilent Technologies GmbH, Waldbronn, Germany) at 4°C overnight. Following washing with PBS the slides were treated with a peroxidase-labeled polymer conjugated to goat anti-rabbit immunoglobulin (Dako EnVision+ System-HRP Labelled Polymer; ready-to-use; #K4003; Dako; Agilent Technologies) according to the manufacturer’s protocol, as the secondary antibody for 30 min at room temperature. The staining was visualized with diaminobenzidine, followed by counterstaining with hematoxylin. Colon cancer cell lines were also immunostained for KIF4A and evaluated for staining intensity.

Expression of these proteins was evaluated using optical microscopy (BX43; Olympus Corporation, Tokyo, Japan) as positive when the nucleus of the cancerous tissue and the total field of view were observed at x400 magnification. Blinded to the patients’ characteristics and clinical outcomes, the staining of each specimen was evaluated. The number of stained cells was counted in per 1,000 cancer cells in the field of cancer tissue by two investigators. The rate of positively stained cells was classified as follows: 0, 0-5; 1, 6-20; 2, 21-50; 3, 51-100%. The staining intensity was scored as 0 (negative), 1 (weak), 2 (moderate) and 3 (intense). The evaluation was expressed as a product of the score of positive rate and staining intensity. Positive staining was defined as a score of >2 and negative staining was scored as 0 or 1.

Western blot analysis. The HCT116 cells were washed twice in ice-cold PBS, pelleted by centrifugation (200 g x g for 5 min) and stored at -80°C. The pellet was resuspended in radioimmuno-precipitation assay buffer (Thermo Fisher Scientific, Inc.) with a Halt Protease Inhibitor Single-Use Cocktail (100X; Thermo Fisher Scientific, Inc.) and centrifuged at 4°C and 17,400 x g for 20 min. Total protein concentrations were measured by the Bradford method using Bradford reagent (Bio-Rad Laboratories, Inc., Hercules, CA, USA) and a Smart Spec 3000 spectrometer (Bio-Rad Laboratories, Inc.). Total proteins isolated from cell lines were separated by 4-12% NuPAGE® Bis-Tris Precast Gel (Thermo Fisher Scientific, Inc.). Tris-Glycine SDS sample buffer (Thermo Fisher Scientific, Inc.) and 3-Mercapto-1,2-propandiol (Wako Pure Chemical Industries, Ltd., Osaka, Japan) were added to the total protein samples and heated at 100°C for 3 min. The 4-12% Tris-Glycine gels (Thermo Fisher Scientific, Inc.) loaded with the 20 µg protein samples were electrophoresed in 100 V for 100 min using Tris-Glycine SDS Running buffer in Invitrogen™ XCell SureLock™ electrophoresis system (Thermo Fisher Scientific, Inc.). Following electrophoresis, the gel was transferred onto the nitrocellulose membrane using an iBlot Gel Transfer Stacks Nitrocellulose, Mini (Thermo Fisher Scientific, Inc.). After transfer, the nitrocellulose membrane was washed with 25 ml TBS for 5 min at room temperature and blocked in SuperBlock blocking buffer in PBS (Thermo Fisher Scientific, Inc.). The protein blots were incubated with the anti-KIF4A antibody (dilution, 1:300; catalog no. #ab122227; Abcam) for
1 h at room temperature and incubated with goat anti-rabbit immunoglobulin G-horseradish peroxidase (Santa Cruz Biotechnology, Inc., Dallas, TX, USA) as the secondary antibody for 30 min at room temperature. The protein levels were quantified using a rabbit monoclonal anti-β-actin antibody (dilution, 1:2,000; catalog no. sc-47778; Santa Cruz Biotechnology, Inc.) as the internal loading control for 1 h at room temperature. Bound antibodies were detected by enhanced chemiluminescence detection reagents (Thermo Fisher Scientific, Inc.) and visualized by autoradiography (ImageQuant™ LAS 4000 IR MultiColor imager; Fujifilm Corporation, Tokyo, Japan).

Small interfering RNA (siRNA) transfection. Knockdown experiments were performed using siRNA oligos for KIF4A (#sc-60888; Santa Cruz Biotechnology, Inc.) and included three target-specific siRNAs and a control siRNA (siRNA-A; #sc-37,007; Santa Cruz Biotechnology, Inc.) according to the manufacturer's protocol. The day prior to transfection, the HCT116 CRC cell line was seeded at a density of 15x10^5 cells/well in a 6-well plate. Transfection using Lipofectamine RNAiMAX (Thermo Fisher Scientific, Inc.) with a final concentration of 10 nM siRNA was performed when the cell density was 30-50% in the 6-well plates and cells were subsequently incubated at 37°C for 48 h.

Cell counting. The cell proliferation rate was assessed using a Cell Counting kit-8 (CCK-8; Dojindo Molecular Technologies, Inc.,Kumamoto, Japan) according to the manufacturer's protocol. Briefly, 2x10^3 HCT116 cells and control cells were plated into each well in 96-well plates. The absorbance was measured after 24, 48, 72, 96 and 120 h of siRNA transfection. After 1 h of incubation with 10 µl of CCK-8 reagent at 37°C, the absorbance was measured at a wavelength of 450 nm using a Benchmark Plus microplate reader (Bio-Rad Laboratories, Inc.).
Statistical analysis. Mann Whitney test, Fisher's exact test, a $\chi^2$ test and Wilcoxon matched pairs test were performed by GraphPad Prism 6.0 (GraphPad Software, Inc. La Jolla, CA, USA). Data of cell viability analysis are shown as the

| Characteristics                  | Total (n=258) | Positive (n=132) | Negative (n=126) | P-value |
|----------------------------------|---------------|------------------|------------------|---------|
|                                 |               |                  |                  |         |
| Age                              |               |                  |                  | 0.64    |
| ≥65                              | 142           | 75               | 69               |         |
| <65                              | 116           | 57               | 59               |         |
| Gender                           |               |                  |                  | 0.49    |
| Male                             | 149           | 79               | 70               |         |
| Female                           | 109           | 53               | 59               |         |
| Stage                            |               |                  |                  | 0.12    |
| 0                                | 10            | 2                | 8                |         |
| I                                | 40            | 23               | 17               |         |
| II                               | 93            | 43               | 50               |         |
| III                              | 75            | 48               | 27               |         |
| IV                               | 40            | 16               | 24               |         |
| Tumor location                   |               |                  |                  | 0.66    |
| Proximal                         | 86            | 42               | 44               |         |
| Distant                          | 89            | 49               | 40               |         |
| Rectum                           | 83            | 41               | 42               |         |
| Histology$^a$                    |               |                  |                  | 0.24    |
| Tub1                             | 120           | 59               | 61               |         |
| Tub2                             | 106           | 63               | 43               |         |
| Por                              | 10            | 3                | 7                |         |
| Muc                              | 19            | 5                | 14               |         |
| Other                            | 3             | 0                | 3                |         |
| Depth                            |               |                  |                  | 0.22    |
| Tis                              | 10            | 2                | 8                |         |
| T1                               | 26            | 13               | 13               |         |
| T2                               | 32            | 22               | 10               |         |
| T3                               | 172           | 95               | 82               |         |
| T4                               | 18            | 5                | 13               |         |
| Lymphatic invasion               |               |                  |                  | 0.35    |
| Absent                           | 155           | 71               | 84               |         |
| Present                          | 95            | 59               | 36               |         |
| Venous invasion                  |               |                  |                  | 0.54    |
| Absent                           | 59            | 28               | 31               |         |
| Present                          | 199           | 104              | 95               |         |
| Lymph node metastasis            |               |                  |                  | <0.01   |
| Negative                         | 155           | 71               | 84               |         |
| Positive                         | 95            | 59               | 36               |         |
| Liver metastasis                 |               |                  |                  | 0.59    |
| Negative                         | 226           | 117              | 109              |         |
| Positive                         | 32            | 15               | 17               |         |

P-values were calculated using Fisher's exact test for age, gender, lymphatic invasion, venous invasion, lymph node metastasis and liver metastasis or a $\chi^2$ test for stage, histology and depth. $^a$Histology was compared between tubular adenocarcinoma and poorly differentiated adenocarcinoma. KIF4A, kinesin family member 4A; IHC, immunohistochemistry; tub1, well differentiated; tub2, moderately differentiated; por, poorly differentiated; muc, mucinous adenocarcinoma; Tis, tumor in situ.
mean ± standard deviation. Survival rate curves were generated using the Kaplan-Meier method and compared by the log-rank test. P<0.05 was considered to indicate a statistically significant difference.

Results

KIF4A is upregulated in CRC samples. KIF4A expression was evaluated using IHC staining in 258 patients with CRC (Fig. 1A). KIF4A expression was positive in 132 cases (51.1% with scores of 2 or 3) and negative in 126 cases (48.9% with scores of 0 or 1). KIF4A expression levels were observed in the nucleus and cytoplasm of cancer cells, whereas no expression was observed in the normal mucosa. mRNA expression levels of KIF4A were analyzed and compared between tumor and adjacent non-cancerous tissues. KIF4A mRNA expression was elevated in tumor tissues in 63 of the 258 available cases (2.26-fold increase; Wilcoxon matched pairs test, P=0.0013) suggesting KIF4A may have an oncogenic role in CRC (Fig. 1B).
KIF4A expression levels and the clinicopathological characteristics were evaluated in patients with CRC (Table I). The positive expression of KIF4A was significantly associated with positive lymph node metastasis (P<0.05). However, KIF4A expression levels were not associated with age, gender, tumor location, TNM stage, depth of invasion, venous invasion or liver metastasis. Notably, as KIF4A is located on chromosome Xq13.1, the clinical significance of KIF4A expression in each gender was investigated. However, KIF4A expression levels did not associate with any clinicopathological characteristics in male or female patients. Additionally, Kaplan-Meier analysis demonstrated that there was no association between the increase in KIF4A levels and overall survival rate (P=0.70; Fig. 1C).

Knockdown of KIF4A inhibition cell growth in colon cancer cells. To evaluate the role of KIF4A in colon cancer progression, gene knockdown technology was used to investigate cell proliferation. KIF4A expression levels in RKO, SW480, Lovo, HCT15, SW48, LS174T, SW620, LS180 and HCT116 colon cancer cell lines were evaluated to select appropriate cells for further experiments in the current study. KIF4A protein expression levels were examined using IHC staining (Fig. 2A) and KIF4A mRNA expression was evaluated using RT-qPCR (Fig. 2B). Concordant with the IHC results, KIF4A mRNA expression was highest in the HCT116 cells compared with the eight other colon cancer cell lines and therefore was used for further experiments.

The knockdown of KIF4A using siRNA oligonucleotides in the HCT116 cells (KIF4A-siRNA) confirmed that the downregulation of KIF4A affected the mRNA and protein levels (Fig. 2C). Although no morphological changes were observed in the KIF4A-depleted cells, cell proliferation was attenuated. There was a significant decrease after 96 h (P<0.05) in the cell growth of the KIF4A-siRNA treated cells compared with the control cells (Fig. 2D).

KIF4A does not associate with positive Ki-67 labeling index results in CRC. To further evaluate whether KIF4A accelerates cell proliferation in CRC, Ki-67 IHC staining was performed on 40 patient tissue samples (Fig. 3). The association between the KIF4A staining results and the Ki-67 labeling index was also investigated; however, no significant association was observed (Mann Whitney test; P=0.49; Fig. 3).

Discussion

The present study identified that KIF4A expression levels are increased in tumor samples from patients with CRC and this may be associated with positive lymph node metastasis. The tumor mRNA and protein expression levels of KIF4A were upregulated in patients with CRC. Previous studies have established that KIF4A expression levels are increased in a number of malignant tumors and are associated with poor patient prognosis (12-16). Concordant with these previous studies, the results of the present study indicate a potential oncogenic role for KIF4A in CRC. However, no significant associations between KIF4A protein expression levels and patient survival rate were observed and further investigation is required to identify if KIF4A may be an effective prognostic biomarker for CRC.

In addition, the present study found that the downregulation of KIF4A suppressed the cell proliferation of colon cancer cells, further suggesting that KIF4A is associated with CRC progression and metastasis. Similarly, it was reported that mutated KIF4A in colon cancer cells lengthens the duration of mitosis and...
The present study was supported by JSPS KAKENHI (grant no. 15K10143).

Acknowledgements

The present study was supported by JSPS KAKENHI (grant no. 15K10143).

References

1. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin 66: 7-30, 2016.
2. Venook AP, Weiser MR and Tepper JE: Colorectal cancer: All hands on deck. Am Soc Clin Oncol Educ Book: 83-89, 2014.
3. de Gramont A, Figer A, Seymour M, Homerin M, Hmishi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947, 2000.
4. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakli M, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355: 1041-1047, 2000.
5. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC and Alberts SR: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22: 23-30, 2004.
6. Tournigand C, André T, Achille E, Liedo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, et al: FOLFIRI followed by FOLFIRX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22: 229-237, 2004.
7. Nakagawa T, Tanaka Y, Matsuoka E, Kondo S, Okada Y, Noda Y, Kanai Y and Hirokawa N: Identification and classification of 16 new kinesin superfamily (KIF) proteins in mouse genome. Proc Natl Acad Sci USA 94: 9654-9659, 1997.
8. Lawrence CJ, Dawe RK, Christie KR, Cleveland DW, Dawson SC, Endow SA, Goldstein LS, Goodson HV, Hirokawa N, Howard J, et al: A standardized kinesin nomenclature. J Cell Biol 167: 19-22, 2004.
9. Mikis H, Okada Y and Hirokawa N: Analysis of the kinesin superfamily: Insights into structure and function. Trends Cell Biol 15: 453-465, 2005.
10. Wadke C, Barisic M, Sigl R, Rauch V, Wolf F, Amaro AC, Tan CH, Pereira AJ, Kutay U, Maihao H, et al: Human chromokinesins promote chromosome congression and spindle microtubule dynamics during mitosis. J Cell Biol 198: 847-863, 2012.
11. Mazumdar M, Sundaresan S and Mistelli T: Human chromokinesins KIF4A functions in chromosome condensation and segregation. J Cell Biol 166: 613-620, 2004.
12. Narayan G, Bourdon V, Chaganti S, Arias-Pulido H, Nanda SV, Rao PH, Gissmann L, Narayan G, Bourdon V, Chaganti S, Arias-Pulido H, Nandula SV, J Cell Biol 166: 8-10, 2004.
13. Taniguchi M, Tahara R, Ishikawa Y, Kusama M, Kohno N, Nakamura Y and Daigo Y: Activation of KIF4A as a prognostic biomarker and therapeutic target for lung cancer. Clin Cancer Res 13: 6624-6631, 2007.
14. Gao J, Sai N, Wang C, Sheng X, Shao Q, Zhou C, Shi Y, Sun S, Qu X and Zhu C: Overexpression of chromokinesin KIF4 inhibits proliferation of human gastric carcinoma cells both in vitro and in vivo. Tumour Biol 32: 53-61, 2011.
15. Minakawa Y, Kasamatsu K, Koike H, Higo M, Nakashima D, Koizumi Y, Sakamoto Y, Ogawa K, Shibata K, Ishida M, Tanazawa H and Uzawa K: Kinesin family member 4A: A potential predictor for progression of human oral cancer. PLoS One 8: e85951, 2013.
16. Zhou JX, Duan Z, Wang J, Sokolov A, Xu J, Chen CZ, Li JJ and Chen HW: Kinesin family deregulation coordinated by bromodomain protein ANCCA and histone methyltransferase MLL for breast cancer cell growth, survival and tamoxifen resistance. Mol Cancer Res 12: 539-549, 2014.
17. Sobin LH GM and Wittekind CH: International Union Against Cancer (UICC) TNM Classification of Malignant Tumors. Oxford, UK, Wiley-Blackwell, 2009.
18. Sobin LH and Compton CC: TNM seventh edition: What's new, what's changed: Communication from the international union against cancer and the american joint committee on cancer. Cancer 116: 5336-5339, 2010.
19. Okano M, Kumatani K, Saito M, Onozawa H, Saito K, Abe N, Ohtake T and Takenoshita S: Upregulated annexin A1 promotes tumor formation via loss of a molecular motor protein. Curr Biol 16: 1559-1564, 2006.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.